News Home

Is Novartis AG (NVS) Stock About to Get Hot Friday?

Friday, October 22, 2021 03:24 PM | InvestorsObserver Analysts
Is Novartis AG (NVS) Stock About to Get Hot Friday?

Overall market sentiment has been high on Novartis AG (NVS) stock lately. NVS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Novartis AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NVS!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With NVS Stock Today?

Novartis AG (NVS) stock is trading at $84.65 as of 3:23 PM on Friday, Oct 22, a loss of -$0.04, or -0.04% from the previous closing price of $84.68. Volume today is below average. So far 1,066,039 shares have traded compared to average volume of 2,030,610 shares. The stock has traded between $84.37 and $84.85 so far today.

More About Novartis AG

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. Click Here to get the full Stock Report for Novartis AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App